Newsletter | June 2024 Recap

Building stronger connections through bolstered CDO capabilities and continuous expansion

Samsung Biologics had an inspiring week to build relations and explore collaboration opportunities at the 2024 BIO International Convention held between June 3-6 in San Diego. We will continue to ensure that we stay adaptable and flexible to meet the needs of our clients and ultimately help the patients they serve. Read this article to get a glimpse of the highlights from BIO 2024.

Samsung Biologics to reinforce innovative and inclusive organizational culture

This month, the company has launched a new initiative to foster a unique and innovative organizational culture as the company strengthens its business competitiveness as a global top-tier CDMO. Dubbed the ‘Samsung Biologics Way,’ the joint initiative, between union and management, seeks to create an inclusive and thriving culture, centered around mutual respect, transparent communication, shared responsibility. Read more

BIO INSIGHTS

Innovation towards next-generation therapeutics

Our commitment to next-generation therapeutics is demonstrated through the construction of our dedicated ADC facility, to be completed by the end of 2024, and strategic collaborations with biotech companies. Read more on how Samsung Biologics can support your ADC pipeline.

Partnerships for success

Samsung Biologics has expanded its capacity more than 20 times within just over a decade. Behind its unprecedented business growth strategy was a mission to become a trusted partner to those developing critical and life-saving drugs worldwide. In this article, we highlight our key service values and how we continue to build on our capabilities to foster trusted partnerships. Read more

MEDIA FOCUS

Streamlining aseptic processes through automation

In aseptic processing, automation serves to mitigate contamination risks and expedite drug product commercialization by enhancing efficiency. In this article, David King, Senior Director of Aseptic Processing, underscores the importance of reducing human error and implementing advanced systems to streamline the manufacturing process. Read more

What are the current investment trends in the pharmaceutical industry, and how are they influencing the sector’s direction?

Pharmaceutical companies continuously make strategic investments to better adapt to the evolving market landscape. In this roundtable discussion, Arushi Narang, senior business strategist, explores how Samsung Biologics is addressing changing trends by expanding into diverse modalities and fostering integrated partnerships. Read more

WEBINAR

Harnessing analytical development to empower process development for successful manufacturing

A well-established analytical development method enables the safe and efficient development of molecules in compliance with regulatory requirements. In this webinar, Steven Lal, lead CDO analytical scientist, shares insights on our capabilities and case studies for our new offerings, Host Cell Protein (HCP) identification and Sequence Variant Analysis (SVA). Learn more

Manufacturing concepts for antibody-drug conjugates

The antibody-drug conjugate (ADC) market is witnessing rapid growth due to increased demand for targeted cancer therapies and improved conjugation technologies. Watch our STAT webinar to gain insights on the latest ADC advancements and discover the critical role CDMOs play in ensuring safe and efficient manufacturing processes. Learn more

Trusted end-to-end CDMO partner for your journey

Given the complexities of biologics development, a CDMO partner that has the capacity and expertise to support the entire drug journey is crucial for success. In this Outsourced Pharma Capacity Update presentation, Thomas Rohrer, Senior Director of Bioconjugate Technology Support, discusses Samsung Biologics’ comprehensive service offerings as well as expansion into the ADC space. Learn more

UPCOMING EVENTS